Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has paid off the remaining balance of approx. $1,300,000 under the convertible debentures (the "Convertible Debentures") previously issued and sold to YA II PN, Ltd. ("Yorkville") in March 2023.
加利福尼亚州帕洛阿尔托，2024年3月19日（GLOBE NEWSWIRE）——专注于收购、开发和商业化用于治疗急慢性疼痛的非阿片类疼痛管理产品的创新创收公司Scilex控股公司（纳斯达克股票代码：SCLX，“Scilex”）今天宣布，它已偿还了可转换债券（“可转换债券”）下约13万美元的剩余余额债券”）此前曾于2023年3月发行并出售给YA II PN, Ltd.（“约克维尔”）。
Scilex has also voluntarily made an early payment in the aggregate amount of $15,000,000 under the senior secured promissory note (the "Oramed Note") issued to Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, "Oramed") in September 2023.
Scilex还根据2023年9月向奥拉美制药公司（纳斯达克股票代码：ORMP，“Oramed”）发行的优先有担保本票（“Oramed票据”）自愿提前支付了总额为1500万美元的款项。
"This is a pivotal moment for Scilex, signaling our readiness to embrace new opportunities and transform the lives of patients with acute and chronic pain while addressing the opioid crisis. With a stronger balance sheet, we are well-positioned to pursue collaborations, expand our current commercialization efforts, and bring additional innovative opioid sparing treatments to market," said Jaisim Shah, Chief Executive Officer and President of Scilex.
“对于Scilex来说，这是一个关键时刻，这表明我们愿意在应对阿片类药物危机的同时，抓住新机遇，改变急慢性疼痛患者的生活。Scilex首席执行官兼总裁Jaisim Shah表示，凭借更强的资产负债表，我们完全有能力开展合作，扩大我们目前的商业化工作，并将更多创新的阿片类药物节约疗法推向市场。